Current practice of colonoscopy surveillance in patients with Lynch syndrome: A multicenter retrospective cohort study in Japan

Yasuyuki Miyakura1,2,3 | Akiko Chino3,4 | Kohji Tanakaya3,5 | Alan Kawarai Lefor2 | Kiwamu Akagi3,6 | Akinari Takao3,7 | Masayoshi Yamada3,8 | Hideyuki Ishida3,9 | Koji Komori3,10 | Kazuhito Sasaki3,11 | Masashi Miguchi3,12 | Keiji Hirata3,13 | Tomoya Sudo3,14 | Toshiaki Ishikawa3,15 | Tatsuro Yamaguchi3,16 | Naohiro Tomita3,17 | Yoichi Ajioka18,19

1Department of Surgery, Saitama Medical Center Jichi Medical University, Saitama, Japan
2Department of Surgery, Jichi Medical University, Tochigi, Japan
3The Committee of Hereditary Colorectal Cancer, Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan
4Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
5Department of Surgery, Iwakuni Clinical Center, Yamaguchi, Japan
6Department of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan
7Department of Gastroenterology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
8Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
9Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
10Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan
11Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
12Department of Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan
13Department of Surgery I, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan
14Department of Surgery, Kurume University, Fukuoka, Japan
15Department of Medical Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan
16Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
17Cancer Treatment Center, Toyonaka Municipal Hospital, Osaka, Japan
18Japanese Society for Cancer of Colon and Rectum, Tokyo, Japan
19Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan

Correspondence
Yasuyuki Miyakura, Department of Surgery, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama-ken 330-8503, Japan.
Email: miyakura@jichi.ac.jp

Abstract
Objectives: Colonoscopy surveillance reduces the incidence of colorectal cancer through the detection and endoscopic removal of adenomas. Current guidelines recommend that patients with Lynch syndrome should have colonoscopy surveillance every 1–2 years starting at the age of 20–25. However, insufficient data are available to evaluate the quality and safety of...
INTRODUCTION

Lynch syndrome is a hereditary autosomal dominant disease that is caused by pathogenic germline variants in one of the DNA mismatch repair genes or deletions in the 3′ ends of the EpCAM, leading to epigenetic silencing of the MSH2. Affected family members have an increased risk of the development of malignancies including colorectal cancer (CRC) and endometrial cancer.1 The risk of development of metachronous CRC after segmental colectomy for primary CRC has been reported to be approximately 28% with a median follow-up of 93 months.2

Colorectal adenomas are recognized as precursors to CRC in patients with Lynch syndrome. Regular colonoscopy surveillance provides the opportunity to prevent the development of CRC by detection and endoscopic removal of adenomas. Current guidelines recommend that patients with Lynch syndrome should have colonoscopy surveillance every 1–2 years starting at age 20–25 years.3–6 A study of interval cancers in patients with Lynch syndrome showed that factors associated with the development of interval cancers included incomplete colonoscopy image, insufficient bowel preparation, and incomplete removal of adenomas during the previous examination.7

In recent years, several quality parameters, such as colonoscopy completion rate, adenoma detection rate (ADR), and colonoscopy-related complication rate, have been proposed to optimize colonoscopy examination.8,9 Evaluations of the quality of colonoscopy are routinely published and are directed toward the complete examination and removal of all polyps in patients with Lynch syndrome. In the present study, we evaluated the quality and safety of colonoscopy surveillance using data from a nationwide Japanese multicenter study.

METHODS

Patients with a confirmed genetic diagnosis of Lynch syndrome were retrospectively registered in a nationwide Japanese multicenter study conducted by the Committee of Hereditary Colorectal Cancer of the Japanese Society for Cancer of the Colon and Rectum. Patients who underwent at least one colonoscopy were included in this study. Colonoscopy completion rate, colonoscopy-related complication rate, proportion having an adequate colonoscopy interval, and ADR were examined. The results for these patients were compared based on the experience of the endoscopists. In addition, the frequency of developing adenomas and CRC during follow-up was compared based on the colonoscopy interval in the 276 patients who had at least two colonoscopies. Colonoscopy was performed using white-light endoscopy with or without magnification or dye-based chromoendoscopy. Colonoscopy was considered complete with visualization of the ileocecal valve or...
appendicular orifice, intubation of the terminal ileum, or visualization of the anastomosis. Colonoscopy interval was divided into <12 months, 12–24 months, and >24 months groups. The experience of each endoscopist was categorized into two levels (> 5000 and < 5000) according to their cumulative number of colonoscopies performed. The cecum and ascending and transverse colon were considered proximal colon, whereas the descending, sigmoid colon, and rectum were considered distal colon.

All polyps were characterized according to the Paris classification.10 Polyps detected during the colonoscopy were removed and endoscopic treatment was performed at the discretion of the endoscopist. Histological diagnoses were made according to the classification of the Japanese Society for Cancer of the Colon and Rectum.11 Serrated lesions included hyperplastic polyps, sessile serrated adenomas/polyps, and traditional serrated adenomas classified according to the World Health Organization histological criteria.12 ADR was defined as the number of colonoscopies at which one or more adenomas were found divided by the total number of colonoscopies performed. Intramucosal cancer classified as stage 0 in the Japanese classification of colorectal carcinoma was categorized as a ‘malignancy’ and was not considered for determination of the ADR.

This study was approved by the Institutional Review Board of each participating institution and the Japanese Society for Cancer of Colon and Rectum and was performed in accordance with the provisions of the Declaration of Helsinki.

STATISTICAL ANALYSIS

The association between two categorical variables was tested using the Chi-squared test or Student’s t-test. Variables with a p-value < 0.05 in the univariate analysis were further evaluated in multivariate analysis using a logistic regression model. SPSS version 27 (SPSS Statistics for Windows; IBM, Armonk, NY) was used for analysis. p-values < 0.05 were considered significant.

RESULTS

Patient demographic data and details of colonoscopy

Patients with Lynch syndrome (n = 316) with confirmed pathogenic germline variants in mismatch repair genes from 13 institutions who underwent colonoscopy were enrolled in this study. Seven patients were excluded due to a lack of information regarding colonoscopy. The remaining patients (n = 309) who underwent 1749 colonoscopies were enrolled in the final analysis. Patient demographics and details of colonoscopy per patient are summarized in Table 1. The median age at first colonoscopy was 50 years (range 14–86). The following pathogenic germline variants were identified: MLH1 (n = 119, 38%), MSH2 (n = 138, 44%), MSH6 (n = 36, 12%), PMS2 (n = 11, 4%), and EPCAM (n = 5, 2%). The median follow-up interval between the first and last colonoscopies was 7 years (range 0–25). There were 236 patients who underwent CRC surgery. Of these, 133 (43%) patients had a previous history of CRC surgery prior to the first colonoscopy, 95 (31%) patients were diagnosed with CRC at the first colonoscopy and underwent CRC surgery, and 25 patients underwent CRC surgery during follow-up. The median number of colonoscopies was five (range 1–18). The percentage of patients with all colonoscopies complete was 94% (291/308). The percentage of patients who underwent colonoscopy with all intervals within 2 years was 76% (211/276), and 71% (196/276) of patients had all colonoscopies complete with all intervals within 2 years. Endoscopic treatment was performed in 219 (71%) patients. The median number of endoscopic treatments per patient was two (range 1–43). The ADR at the first colonoscopy was 25% (78/309) and in patients without previous CRC surgery was 22% (39/176). The adenoma and intramucosal cancer detection rate at the first colonoscopy was 34% (106/309). The number of patients who had at least one or more adenoma, intramucosal cancer, or serrated polyps during the follow-up interval was 175 (57%), 95 (31%), and 86 (28%), respectively. There were four patients with complications (perforation = 1, bleeding = 2, and abdominal discomfort = 1) in the present study. The patient with abdominal discomfort during endoscopic mucosal resection needed discontinuation of treatment. One of two patients with bleeding needed endoscopic hemostasis. The last patient with perforation needed emergency surgical intervention. All were associated with endoscopic treatment.

Clinical characteristics for each colonoscopy

The clinical characteristics of colonoscopies are shown in Table 2. The colonoscopy completion rate was 98.8% (1630/1649). The completion rate was significantly lower in colonoscopies of patients who had not undergone CRC surgery (97.1% [501/516]) compared with those who had undergone surgery (99.6% [1129/1133]; p < 0.001). Colonoscopy intervals of more than 24 months occurred in 6% (78/1397). Endoscopic treatment was performed during 634 (36%) colonoscopies and 1184 polyps were resected. The mean number of resected polyps per colonoscopy was 0.68 ± 1.2. The following pathologies were identified: adenoma (n = 807), intramucosal cancer (n = 191), and
| TABLE 1 | Patient demographic data and details of colonoscopy |
|---------|-------------------------------------------------|
| **Patients with Lynch syndrome** | 309 |
| Median age at first colonoscopy (range) | 50 (14–86) |
| Sex—Male:Female | 144:165 |
| Presence of causative genes of Lynch syndrome | |
| *MLH1* | 119 (38%) |
| *MSH2* | 138 (44%) |
| *MSH6* | 36 (12%) |
| *PMS2* | 11 (4%) |
| *EPCAM* | 5 (2%) |
| Median follow-up between first and last colonoscopy, years (range) | 7 (0–25) |
| Patients undergoing surgery for CRC | 236 |
| Patients with previous CRC surgery prior to the first colonoscopy | 133 (43%) |
| Patients without previous CRC surgery during follow-up | 116 |
| Patients diagnosed with CRC with surgery during follow-up | 17 |
| Patients without previous CRC surgery prior to the first colonoscopy | 103 (33%) |
| Patients diagnosed with CRC at the first colonoscopy who underwent surgery | 95 |
| Patients with CRC surgery during follow-up | 8 |
| Colonoscopy | |
| Median number of colonoscopies (range) | 5 (1–18) |
| Percentage of patients with all colonoscopies complete | 94% (291/308) |
| Percentage of patients with ≤ 24 months interval between colonoscopies | 76% (211/276) |
| Percentage of patients without incomplete colonoscopy and >24 months interval between colonoscopies | 71% (196/276) |
| Endoscopic treatment | |
| Underwent endoscopic treatment | 219 (71%) |
| Median number of endoscopic treatments/patient (range) | 2 (1–43) |
| Adenoma detection rate at first colonoscopy | 25% (78/309) |
| Adenoma and intramucosal cancer detection rate at first colonoscopy | 34% (106/309) |
| Adenoma detection rate at first colonoscopy in patients without previous CRC surgery | 22% (39/176) |
| Patients with one or more polyps resected by endoscopic treatment during follow-up | |
| With adenoma | 175 (57%) |
| With intramucosal cancer | 95 (31%) |
| With serrated polyps | 86 (28%) |
| Complications related to endoscopic treatment | |
| Any complication | 4 (1.2%) |
| Bleeding necessitating repeat colonoscopy | 2 (0.6%) |
| Bleeding necessitating endoscopic hemostasis | 1 (0.3%) |
| Perforation needing emergency surgical intervention | 1 (0.3%) |

†Excluding one patient who underwent sigmoid colonoscopy without preparation.
‡Excluding patients who had only one colonoscopy.

Complications related to endoscopic treatment

The rate of bleeding requiring endoscopic hemostasis was 0.16% (1/607) per colonoscopy with endoscopic treatment (Table 3). The rate of perforation needing surgical repair was 0.16% (1/607) for colonoscopies.
TABLE 2 Clinical characteristics of each colonoscopy

| Total number of colonoscopies | 1749 |
|--------------------------------|------|
| Colonoscopy completion rate   | 98.8% (1630/1649) |
| Completion rate in patients without previous CRC surgery | 97.1% (501/516) |
| Completion rate in patients with previous CRC surgery | 99.6% (1129/1133) |
| Colonoscopy interval<sup>‡</sup> | |
| <12 months                     | 383  |
| 12–24 months                  | 936  |
| >24 months                    | 78   |
| Endoscopic treatment          | |
| Colonoscopy with endoscopic treatment (%) | 634 (36%) |
| Resected polyps               | 1184 |
| Median number of resected polyps/colonoscopy (range) | 0 (1-10) |
| Mean number of resected polyps/colonoscopy | 0.68 ± 1.2 |
| Pathology of polyps resected endoscopically | |
| Adenoma                       | 807  |
| Intramucosal cancer           | 191  |
| Serrated lesions              | 157  |
| Others                        | 33   |
| Adenoma detection rate among all colonoscopies | 26% (462/1749) |
| Adenoma and intramucosal cancer detection rate among all colonoscopies | 32% (558/1749) |
| Complications related to endoscopic treatment | |
| Colonoscopies with any complication related to endoscopic treatment | 0.2% (4/1652) |
| Colonoscopies with bleeding needing repeat colonoscopy | 0.1% (2/1652) |
| Colonoscopies with bleeding needing endoscopic hemostasis | 0.06% (1/1652) |
| Colonoscopies with perforation needing emergency surgical intervention | 0.06% (1/1652) |

<sup>‡</sup>excluding colonoscopy for purpose of endoscopic treatment, preoperative marking and examination of anastomosis, colonoscopy without preparation, colonoscopy for patients with stenosis due to cancer, colonoscopy for patients who underwent total colectomy, and sigmoidoscopy.  
<sup>‡</sup>intervals were examined among patients who underwent colonoscopy more than two times.  
<sup>§</sup>colonoscopies with information of complication.

Abbreviation: CRC, colorectal cancer.

TABLE 3 Complications related to endoscopic treatment

| Complications                                                                 | Frequencies |
|-------------------------------------------------------------------------------|-------------|
| Any complication related to endoscopic treatment                             | 0.2% (4/1652) |
| Bleeding after endoscopic treatment needs endoscopic hemostasis              |             |
| Bleeding among all colonoscopy procedures                                     | 0.06% (1/1652) |
| Bleeding among all colonoscopies with endoscopic treatment                   | 0.16% (1/607) |
| Bleeding among all colonoscopies with endoscopic treatment for intramucosal cancer | 0.66% (1/152) |
| Perforation after endoscopic treatment needing emergency surgery              |             |
| Perforation among all colonoscopy procedures                                  | 0.06% (1/1652) |
| Perforation among all colonoscopies with endoscopic treatment                | 0.16% (1/607) |
| Perforation among all colonoscopies with endoscopic treatment for intramucosal cancer | 0.66% (1/152) |

<sup>§</sup>colonoscopies with information of complication.

performed with endoscopic treatment. Perforation occurred during endoscopic mucosal resection of a 25-mm 0-IIa intramucosal carcinoma in the transverse colon after right hemicolectomy. Bleeding occurred after endoscopic snare polypectomy of a 6-mm 0-IIa intramucosal carcinoma in the transverse colon after partial resection of the sigmoid colon. The frequencies of bleeding and perforation were 0.66% (1/152) and 0.66% (1/152) for colonoscopies performed with endoscopic treatment for intramucosal cancer, respectively.
TABLE 4 Colon polyps detected and colonoscopy intervals

| Interval              | Number of polyps detected |
|-----------------------|---------------------------|
| 12–24 months (936 colonoscopies) |                          |
| Adenomas              | 232 (25%)                 |
| Intramucosal cancers  | 42 (4.5%)                 |
| Invasive cancers      | 9 (0.96%)                 |
| Interval more than 24 months (78 colonoscopies) |                          |
| Adenomas              | 16 (21%)                  |
| Intramucosal cancers  | 10 (13%)                  |
| Invasive cancers      | 5 (6%)                    |

p-values

| Number of polyps detected |
|---------------------------|
| NS                        |
| 0.01                      |

Abbreviation: NS, not significant.

TABLE 5 Colonoscopy parameters and the endoscopist experience

| Completion rate | 5000 or more | <5000 | p-values |
|-----------------|--------------|-------|----------|
| Colonoscopy-related complication rate | 98.4% (718/730) | 99.2% (900/907) | NS |
| Mean number of detected adenomas | 0.54 | 0.40 | 0.03 |
| Mean number of detected intramucosal cancers | 0.15 | 0.08 | 0.01 |
| Mean number of detected serrated polyps | 0.09 | 0.09 | NS |

†colonoscopies with information of complication.

Abbreviation: NS, not significant.

Colon polyp detection and colonoscopy intervals

The relationship between the development of polyps and the colonoscopy interval (12–24 months: 936 colonoscopies and >24 months: 78 colonoscopies) is shown in Table 4. There was no difference in the rate of development of adenomas between the two groups. The frequencies of developing intramucosal cancer and invasive cancer were significantly higher in the group with an interval >24 months (p = 0.01, 0.01, respectively).

Colonoscopy parameters and endoscopist’s experience

Data were compared between two levels of experience of the endoscopist (Table 5). There was no difference in the completion rate or complication rate between the two groups. However, the mean number of detected adenomas and intramucosal cancers was significantly higher in colonoscopies performed by more experienced endoscopists (p = 0.03, p = 0.01, respectively).

Multivariate analysis for the detection of intramucosal cancer

Interval time and the endoscopist’s skill were significantly associated with the detection of intramucosal cancer in each analysis (Tables 4 and 5). They were further evaluated by multivariate analysis using a logistic regression model. Both of these independent factors were significantly associated with the detection of intramucosal cancer (Table 6).

DISCUSSION

This study assessed the quality and safety of colonoscopy surveillance for patients with Lynch syndrome registered in a nationwide Japanese multicenter study. The colonoscopy completion rate was 98.8% per colonoscopy and history of CRC surgery was significantly associated with a higher completion rate. Seventy-one (196/276) percent of patients underwent complete colonoscopies with adequate intervals for all colonoscopies. All complications were associated with endoscopic treatment, and the rates of bleeding necessitating hemostasis and perforation needing surgical intervention were both 0.16% for colonoscopies performed with endoscopic treatment. The ADR and adenoma and intramucosal cancer detection rates at
the first colonoscopy were 25% (78/309) and 34% (106/309) among all patients, respectively. Although there was no difference in the completion and complication rates according to the experience level of the endoscopist, the detection rate of adenoma and intramucosal cancer was significantly higher among more experienced endoscopists. The proportion of intramucosal cancer or invasive CRCs detected was significantly higher for patients with an interval of more than 24 months compared to less than 24 months. This was the first study to assess the current quality and safety of colonoscopy surveillance for patients with Lynch syndrome in a nationwide survey in Japan.

Colonoscopy has variable quality depending on the endoscopist’s skill and the patient’s background. In the management of Lynch syndrome, patients are younger and repeated colonoscopies at short intervals are needed for lifelong surveillance. Moreover, colonoscopy in patients with Lynch syndrome should be precisely performed with special attention to the right colon. Thus, the colonoscopy completion rate is an important quality parameter in such patients. In the present study, the completion rate was 98.8% per colonoscopy, similar to that reported (92%–99%) in a previous study. The completion rate was significantly lower in patients without a history of prior surgery (97.1%) compared with those with a history of surgery (99.6%) (p < 0.001). Although adhesions associated with previous abdominal surgery decrease the completion rate, the reduction of the length of the colon due to a past history of CRC surgery may be associated with an increased completion rate in patients with Lynch syndrome.

The rates of bleeding and perforation during colonoscopy performed with and without endoscopic treatment are considered to be quality and safety indicators in some guidelines. The rate of post-polypectomy bleeding and perforation is recommended to be ≤1/100 and ≤1/500 colonoscopies. In the present study, the rates of bleeding and perforation for colonoscopies performed with endoscopic treatment were both 0.16% (1/607), which is within the acceptable range. Both of the polyps associated with complications were flat-type intramucosal cancers in the transverse colon. Complications related to endoscopic treatment tended to occur with large, flat polyps. Clipping has been used recently to prevent or treat bleeding or perforation. The rates of bleeding and perforation in the present study were consistent with the proposed standard. Thus, colonoscopy surveillance with endoscopic treatment was performed safely for patients with Lynch syndrome.

Colorectal adenomas are recognized as the main precursor to CRC in patients with Lynch syndrome. The efficacy of colonoscopy screening is based on the concept of a “clean” colon by removing all of the adenomas identified. The ADR is a widely accepted benchmark for the quality of screening colonoscopy. ADRs in colonoscopy surveillance using standard white light have been reported to be 25%–35% for the general population and 20%–31% for patients with Lynch syndrome. ADRs for patients with Lynch syndrome are not so high compared to those of the general population. In the present study, the ADR and adenoma, and intramucosal cancer detection rates at the first colonoscopy were 25% (78/309) and 35% respectively, which are comparable with results in previous reports. The ADR in the present study was based mainly on white-light endoscopy. Recent advanced imaging techniques, such as virtual chromoendoscopy, improve the ADR. There is evidence that with each 1.0% increase in ADR, there is an associated 3.0% decrease in the risk of developing an interval CRC. The European Society of Gastrointestinal Endoscopy guideline recommends at least the use of a high-definition endoscope in patients with Lynch syndrome. The quality of colonoscopy in the present study was acceptable but using more advanced colonoscopy techniques may improve ADR in patients with Lynch syndrome.

In the present study, although there was no difference in completion and complication rates according to the level of experience of the endoscopist, the number of detected adenomas and intramucosal cancers was significantly higher in colonoscopies performed by more experienced endoscopists. A population-based study from Canada found that the risk of complications, such as perforation and bleeding, was increased threefold in procedures performed by endoscopists who had performed fewer than the threshold of 300 colonoscopies per year. In addition, the ADR was positively associated with the level of experience of the endoscopist. A minimum lifetime experience of 1000 examinations and a minimum annual number of 150 screening colonoscopies is recommended by the English NHS Bowel Cancer Screening Program. High-volume experienced endoscopists may have an important role in minimizing the number of missed polyps.

Several factors may predict failure to prevent the development of cancer during follow-up in patients with Lynch syndrome. The adenoma-carcinoma sequence appears to be accelerated in patients with Lynch syndrome, with the polyp to cancer dwell time estimated at 35 months compared with 10–15 years for sporadic cancers. The post-colonoscopy risk for developing CRC was significantly lower in carriers receiving high-quality surveillance. Strict annual or biennial surveillance may minimize the risk of the development of CRC. In the present study, 24% (65/276) of patients underwent at least one colonoscopy with an inadequate interval of >24 months. The proportion of patients developing intramucosal and invasive CRC was significantly higher in patients with an inadequate interval compared to those with an adequate interval. In the general population, a 10-year colonoscopy interval is
considered sufficient to successfully lower the incidence of CRC.\textsuperscript{35} However, in patients with Lynch syndrome, the progression to CRC has been suggested to be accelerated compared to the general population.\textsuperscript{36} Appropriate surveillance intervals for complete colonoscopy may minimize the risk of developing CRC.

There were several limitations to the present study. First, this was a retrospective study; however, a strength of this study was that the data were derived from a Japanese nationwide multicenter study of the largest Japanese cohort of patients with Lynch syndrome. Second, information regarding bowel preparation and withdrawal time as indicators of quality was lacking. These factors affected completion and ADR. Third, the study lacked sufficient data for the use of high-definition colonoscopy and dye-based chromoendoscopy. These advanced colonoscopy techniques may improve ADR. Finally, the study lacked detailed information about the kind of endoscopic treatment employed such as cold polypectomy, hot polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection. This information helps to delineate the precise quality and safety of endoscopic treatment for colorectal polyps in patients with Lynch syndrome.

In conclusion, the present study reports the current status of quality and safety of colonoscopy surveillance for patients with Lynch syndrome in a nationwide survey in Japan. These findings suggest that high-volume experienced endoscopists and appropriate surveillance intervals may minimize the risk of developing CRC in patients with Lynch syndrome.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

FUNDING INFORMATION
None.

ORCID
Yasuyuki Miyakura \textsuperscript{16} https://orcid.org/0000-0002-4464-2465
Alan Kawarai Lefor \textsuperscript{16} https://orcid.org/0000-0001-6673-5630

REFERENCES
1. Lynch HT, Smyrk TC, Watson P \textit{et al.} Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review. \textit{Gastroenterology} 1993; \textbf{104}: 1535–49.
2. Malik SS, Lythgoe MP, McPhail M, Monahan KJ. Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: A systematic review and meta-analysis. \textit{Farn Cancer} 2018; \textbf{17}: 557–64.
3. Syngal S, Brand RE, Church JM \textit{et al.} ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. \textit{Am J Gastroenterol} 2015; \textbf{110}: 223–62.
4. Giardiello FM, Allen Jl, Axlund JE \textit{et al.} Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-Society Task Force on colorectal cancer. \textit{Gastroenterology} 2014; \textbf{147}: 502–26.
5. Niv Y, Moeslein G, Vasan HF \textit{et al.} Quality of colonoscopy in Lynch syndrome. \textit{Endosc Int Open} 2014; \textbf{2}: E252–5.
6. Tomita N, Ishida H, Tanakaya K \textit{et al.} Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer. \textit{Int J Clin Oncol} 2021; \textbf{26}: 1353–419.
7. Haanstra JF, Vasan HF, Sanduleanu S \textit{et al.} Quality colonoscopy and risk of interval cancer in Lynch syndrome. \textit{Int J Colorectal Dis} 2013; \textbf{28}: 1643–9.
8. Rex DK, Petrini JL, Baron TH \textit{et al.} Quality indicators for colonoscopy. \textit{Gastrointest Endosc} 2006; \textbf{63}: S16–28.
9. Kaminski MF, Regula J, Kraszewska E \textit{et al.} Quality indicators for colonoscopy and the risk of interval cancer. \textit{N Engl J Med} 2010; \textbf{362}: 795–803.
10. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon: November 30 to December 1, 2002. \textit{Gastrointest Endosc} 2003; \textbf{58}: S3–43.
11. Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma, Tokyo: Kanehara & Co., Ltd., 2009.
12. Bosman F, Carneiro F, Hruban RH. World Health Organization Classification of Tumors of the Digestive System, 4th edn, Lyon: IARC, 2010.
13. Newton K, Green K, Laloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. \textit{Colorectal Dis} 2015; \textbf{17}: 38–46.
14. Vale Rodrigues R, Claro I, Lage P \textit{et al.} Colorectal cancer surveillance in Portuguese families with Lynch syndrome: A cohort study. \textit{Int J Colorectal Dis} 2018; \textbf{33}: 695–702.
15. Sánchez A, Roos VH, Navarro M \textit{et al.} Quality of colonoscopy is associated with adenoma detection and postcolonoscopy colorectal cancer prevention in Lynch syndrome. \textit{Clin Gastroenterol Hepatol} 2020; \textbf{20}: 611–21 e9.
16. Lee SK, Kim TI, Shin SJ, Kim BC, Kim W. Impact of prior abdominal or pelvic surgery on colonoscopy outcomes. \textit{J Clin Gastroenterol} 2006; \textbf{40}: 711–6.
17. Rex DK, Petrini JL, Baron TH \textit{et al.} Quality indicators for colonoscopy. \textit{Am J Gastroenterol} 2006; \textbf{101}: 873–85.
18. Rex DK, Schoenfeld PS, Cohen J \textit{et al.} Quality indicators for colonoscopy. \textit{Am J Gastroenterol} 2015; \textbf{110}: 72–90.
19. Kaminski MF, Thomas-Gibson S, Bugajski M \textit{et al.} Performance measures for lower gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. \textit{United European Gastroenterol} 2017; \textbf{5}: 309–34.
20. Tholoor S, Tsagkournis O, Basford P, Bhandari P. Managing difficult polyps: Techniques and pitfalls. \textit{Ann Gastroenterol} 2013; \textbf{26}: 114–21.
21. Rembacken B, Hassan C, Riemann JF \textit{et al.} Quality in screening colonoscopy: Position statement of the European Society of Gastrointestinal Endoscopy (ESGE). \textit{Endoscopy} 2012; \textbf{44}: 957–68.
22. Buchner AM, Shahid MW, Heckman MG \textit{et al.} High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. \textit{Clin Gastroenterol Hepatol} 2010; \textbf{8}: 364–70.
23. Dinesen L, Chua TJ, Kaffes AJ. Meta-analysis of narrow-band imaging versus conventional colonoscopy for adenoma detection. \textit{Gastrointest Endosc} 2012; \textbf{75}: 604–11.
24. Rex DK. Detection measures for colonoscopy: Considerations on the adenoma detection rate, recommended detection thresholds, withdrawal times, and potential updates to measures. \textit{J Clin Gastroenterol} 2020; \textbf{54}: 130–5.
25. Tziatzios G, Gkolfakis P, Lazaridis LD \textit{et al.} High-definition colonoscopy for improving adenoma detection: A systematic
26. Houwen BBSL, Mostafavi N, Vleugels JLA et al. Dye-based chromoendoscopy in patients with Lynch syndrome: An individual patient data meta-analysis of randomized trials. *Am J Gastroenterol* 2021; 116: 825–8.

27. Rivero-Sánchez L, Arnau-Collell C, Herrero J et al. White-light endoscopy is adequate for Lynch syndrome surveillance in a randomized and noninferiority study. *Gastroenterology* 2020; 158: 895–904.

28. Corley DA, Jensen CD, Marks AR et al. Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med* 2014; 370: 1298–306.

29. Kaminski MF, Regula J, Kraszewska E et al. Quality indicators for colonoscopy and the risk of interval cancer. *N Engl J Med* 2010; 362: 1795–803.

30. Bisschops R, East JE, Hassan C et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline—Update 2019. *Endoscopy* 2019; 51: 1155–79

31. Rabeneck L, Paszat LF, Hilsden RJ et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. *Gastroenterology* 2008; 135: 1899–906

32. Lee TJ, Rees CJ, Blanks RG et al. Colonoscopic factors associated with adenoma detection in a national colorectal cancer screening program. *Endoscopy* 2014; 46: 203–11.

33. Barton R. Validity and reliability of an accreditation assessment for colonoscopy. *Gut* 2008; 57: A4

34. Edelstein DL, Axilbund J, Baxter M et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. *Clin Gastroenterol Hepatol* 2011; 9: 340–3.

35. Stock D, Paszat LF, Rabeneck L. Colorectal cancer mortality reduction is associated with having at least 1 colonoscopy within the previous 10 years among a population-wide cohort of screening age. *Gastrointest Endosc* 2016; 84: 133–41.

36. Dove-Edwin I, de Jong AE, Adams J et al. Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome. *Gastroenterology* 2006; 130: 1995–2000.